Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Ductal carcinoma in situ (DCIS) of the breast detected by mammogram at the time of diagnosis~  * Unicentric~ * Lesions ≤ 2.5 cm~ * Low nuclei grade (NG1) or intermediate nuclei grade (NG2) with necrosis in \< one third of the involved ducts~ * Inked margins ≥ 3 mm~ * Clinically node negative~ * Non-palpable~* No suspicious areas on post-operative mammogram taken within 12 weeks after final surgery~* No bloody nipple discharge~* No more than 12 weeks since prior final surgery (arm II only)~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 26 and over~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant or nursing~* No active connective tissue disorders (e.g., lupus or scleroderma)~* No prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* No other concurrent hormonal therapy (e.g., raloxifene, hormone replacement therapy, or birth control pills)~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: 26 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Observation +/- tamoxifen for 5 years (Type: ACTIVE_COMPARATOR): Observation +/- tamoxifen 20 mg per day for 5 years
- Radiation therapy +/- tamoxifen for 5 years (Type: EXPERIMENTAL): Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years

Based on this trial design, predict the completion outcome and termination type (if applicable).